Aptevo Therapeutics Inc. · NASDAQ:APVO
Aptevo Therapeutics — Investor Presentation (January 2019)
31 slides from Aptevo Therapeutics's investor presentation, Jan 9, 2019
Slide 1: Aptevo Therapeutics Investor Presentation January 2019
Aptevo Therapeutics Investor Presentation January 2019 Exhibit 99.2
Slide 2: Forward-looking statements
This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including our financial guidance, product portfolio, product sales, capabilities and any other statements contai
Slide 3: Aptevo: At a Glance
Aptevo: At a Glance Leading Oncology Platform Innovative ADAPTIR platform technology utilizing a novel approach in the highly attractive immuno-oncology field Leveraging Technology Targeted investments in bispecific ADAPTIR therapeutics Robust IP Estate Own and exclusively licensed patents and trade
Slide 4: Aptevo – A Compelling Investment Opportunity
Aptevo – A Compelling Investment Opportunity Solid cash position to advance R&D and commercial strategy 1 2 3 4 5 Strong leadership team with a track record of execution Advancing ADAPTIR to generate novel best-in-class antibody therapeutics Broad pipeline of wholly-owned bispecific antibody candida
Slide 5: Agenda
Agenda Executing on our Strategy ADAPTIR – Developing Novel Protein Therapeutics Impressive Bispecific Antibody Portfolio IXINITY – A Growing Commercial Opportunity Summary INNOVATING APTEVO Therapeutics
Slide 6: Experienced Leadership Team
Experienced Leadership Team Senior Management Marvin White – President & CEO Former Emergent Director; Former CFO, St. Vincent’s Health; Former Exec. Director & CFO, Lilly USA Jeff Lamothe – SVP, CFO Former Emergent VP, Finance; Former CFO, Cangene Corporation Randy Maddux – SVP, Chief Manufacturing
Slide 7: Executing on our Strategy to Build Value
Executing on our Strategy to Build Value Objective Result Ensure Aptevo is solidly capitalized $65M Emergent funding $20M MidCap debt funding $75M commercial asset sale $38M estimated cash balance at 12/31/18 $35M share purchase agreement with Lincoln Park Capital Build robust platform of ADAPTIR bi
Slide 8: Product/Candidate Development Stage and Milestones
Product/Candidate Target Technology Indication Pre-Clinical Clinical Development Stage Marketed Milestones/Highlights Phase I Phase II Phase III COMMERCIAL PORTFOLIIO IXINITY Recombinant Protein Hemophilia B $23M (12/31/18 - estimate) $10.9M (2017) $9.8M (2016) ADAPTIR PORTFOLIO APVO436 CD3/CD123 AD
Slide 9: Agenda
Agenda Executing On Our Strategy ADAPTIR – Developing Novel Protein Therapeutics Impressive Bispecific Antibody Portfolio IXINITY – A Growing Commercial Opportunity Summary
Slide 10: Bispecific Antibodies and ADAPTIR Platform
Bispecific Antibodies Emerging technology Extensive opportunity to create novel therapeutics for treatment of cancer and autoimmune diseases ADAPTIR™ Robust and flexible platform technology Potential to generate novel best-in-class monospecific and bispecific antibody therapeutics Generates bispecif
Slide 11: Key Advantages of ADAPTIR Bispecifics
Key Advantages of ADAPTIR Bispecifics* Structure Property ADAPTIR Increased Potency and Stability Reduced Cytokine Release Longer Half-Life Optimal Manufacturability ü ü ü ü *Based on current preclinical data for various ADAPTIR candidates Binding Domain 1 Binding Domain 2
Slide 12: ADAPTIR – A Versatile Therapeutic Platform
Platform produces drugs with multiple mechanisms to stimulate the body’s own immune system for the treatment of autoimmune diseases and cancer ADAPTIR – A Versatile Therapeutic Platform T-cell Engagers CD3 + Tumor Antigen T-cell Co-stimulators + Tumor Antigen (e.g. 4-1BB) Targeted Cytokines IL-10 AI
Slide 13: ADAPTIR Candidates are More Potent than Heterodimer Bispecifics
ADAPTIR RTCC molecules have more potent tumor killing compared to heterodimer formats targeting the same tumor antigen Lower concentrations (EC50) needed to achieve same potency in Tumor Lysis Assays ADAPTIR Candidates are More Potent than Heterodimer Bispecifics ADAPTIR T cell Tumor cell lysis ADAP
Slide 14: ADAPTIR Candidates Induce Lower Levels of Cytokines
ADAPTIR Candidates Induce Lower Levels of Cytokines than Competitor Formats* Cytokines measured after 20 hr stimulation of T cells with ADAPTIR and tumor cells ADAPTIR bispecifics generate lower levels of cytokines when tumor antigen present compared to other formats targeting the same tumor antigen
Slide 15: Agenda
Agenda Executing On Our Strategy ADAPTIR – Developing Novel Protein Therapeutics Impressive Bispecific Antibody Portfolio IXINITY – A Growing Commercial Opportunity Summary
Slide 16: APVO436 – Best-in-Class Preclinical Candidate Targeting CD123
APVO436 – Best-in-Class Preclinical Candidate Targeting CD123 CANDIDATE OPPORTUNITY FUNCTION/MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS Next generation ADAPTIR (CD123 x CD3) T cell engager Potential best-in-class candidate; preclinical studies show key differentiation from competitor forma
Slide 17: APVO436 – Key Competitor Differentiation
Best-in-Class CD123 x CD3 Bispecific APVO436 – Key Competitor Differentiation Novel structure Supports traditional antibody-like manufacturing processes Single gene construct and CHO production cell line Improved half-life 12.5 days (rodents); 3.5 days (NHPs) Potential for improved dosing regime in
Slide 18: APVO436 and MGD006 Induce Comparable T-cell Cytotoxicity
APVO436 and Aptevo-Generated MGD006 Induce Comparable T-cell Cytotoxicity E:T Ratio APVO436 (EC50) Aptevo-MGD006 (EC50) 10:1 2.1 pM 1.7 pM 5:1 5.5 pM 3.2 pM 1:1 38.1 pM 20.9 pM 0.5:1 n/a 30.3 pM 0.1:1 n/a 39.4 pM CD123 x CD3 Bispecific Potency in 51Cr KG-1a RTCC Assay 51Cr Release Cytotoxicity Flow
Slide 19: APVO436 Induces Endogenous T-cell Proliferation and CD123+ Depletion
In normal and AML subject samples APVO436: Induced rapid activation and proliferation of endogenous T cells Showed robust responses to APVO436 in AML subjects with low endogenous T cell numbers Showed a progressive reduction of CD123+ cells over the 96-hour culture period APVO436 Induces Endogenous
Slide 20: APVO436 Eliminates Skeletal Tumor Burden in Mice
Treatment of established disseminated MOLM-13 tumors in mice with APVO436 resulted in rapid reduction in skeletal tumor burden APVO436 Eliminates Skeletal Tumor Burden in Mice with Established Tumors NSG mice implanted IV with MOLM-13 cells on Day 0 T cells implanted on Day 4 Drug delivered after tu
Slide 21: APVO210 – Preclinical Candidate for AIID
APVO210 – Preclinical Candidate for AIID with a Novel Mechanism of Action CANDIDATE OPPORTUNITY FUNCTION/ MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS Targeted cytokine based on ADAPTIR platform Anti-CD86 scFv delivers IL-10 specifically to antigen presenting (CD86+) cells to suppress inflam
Slide 22: APVO210 Retains Immunosuppressive Function of IL-10
T B DC10 Regulatory DC & regulatory T cells Cytotoxicity Ab generation Tr1 Proinflammatory cytokines Ag Presentation M DC Anti-CD86 scFv Monomeric IL-10 IL-10 APVO210 APVO210 Retains the Immunosuppressive Function of IL-10 Without Immunostimulation
Slide 23: ALG.APV-527 – Preclinical Candidate
ALG.APV-527 – Preclinical Candidate with Broad Potential Therapeutic Opportunity CANDIDATE OPPORTUNITY FUNCTION/MOA INDICATIONS DEVELOPMENT STAGE PARTNERSHIP STATUS Engages T-cells through co-stimulatory receptor 4-1BB Reactivates antigen-primed T cells to specifically kill tumor cells; Promotes CD8
Slide 24: ALG.APV-527 Targeted Immunotherapeutic Bispecific Antibody
ALG.APV-527 Targeted Immunotherapeutic Bispecific Antibody Targeting 41BB x 5T4 New MOA demonstrates ADAPTIR versatility Simultaneously targets 4-1BB - costimulatory receptor, member of TNFR super family 5T4 tumor antigen Promising approach for targeted immunotherapy Targets T cells previously activ
Slide 25: Agenda
Agenda Executing On Our Strategy ADAPTIR – Developing Novel Protein Therapeutics Impressive Bispecfic Antibody Portfolio IXINITY – A Growing Commercial Opportunity Summary
Slide 26: IXINITY – Recombinant Factor IX for Hemophilia B
IXINITY – Recombinant Factor IX for Hemophilia B [coagulation factor IX (recombinant)] An intravenous recombinant human coagulation factor IX therapeutic for use in patients with Hemophilia B Standard half-life, recombinant factor IX treatment for Hemophilia B Indication: Individuals with Hemophilia
Slide 27: IXINITY – 2019 New Growth Initiatives
Launch of new 3,000 IU assay Q2 2019 Enhanced convenience (travel / storage) Attractive option for ‘severe’ Hemophilia B patients Pediatric label expansion Phase 4 post-marketing study Q3 2019 Pilot study in previously treated patients under 12 years of age showed: IXINITY safe and well tolerated Co
Slide 28: Agenda
Agenda Executing On Our Strategy ADAPTIR – Developing Novel Protein Therapeutics Impressive Bispecific Antibody Portfolio IXINITY – A Growing Commercial Opportunity Summary
Slide 29: Financial Snapshot
Financial Snapshot Shares Outstanding 22,808,416 12/31/2018 Cash $38M 12/31/2018 (Estimate) Debt $20M MidCap Financial IXINITY Revenue 2018 2017 2016 2015 $ 23.0M (Estimate) $ 10.9M $ 9.8M $ 1.0M 2019 Cash Burn $36M - $40M Projected Cash Burn
Slide 30: 2019 Milestones
2019 Milestones Program Commence Phase 1 clinical trial of APVO210 Launch new 3,000 IU IXINITY assay Commence patient dosing in Phase 4 IXINITY study Report preliminary Phase 1 safety data for APVO436 Report preliminary Phase 1 safety data for APVO210 File CTA submission for Phase 1 study of ALG.APV
Slide 31: Aptevo – A Compelling Investment Opportunity
Aptevo – A Compelling Investment Opportunity Solid cash position to advance R&D and commercial strategy 1 2 3 4 5 Strong leadership team with a track record of execution Advancing ADAPTIR™ to generate novel best-in-class antibody therapeutics Broad pipeline of wholly-owned bispecific antibody candid
Aptevo Therapeutics — Investor Presentation (January 2019) on 6ix